Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment
Objective: To assess TDIS and global AIMS measures change trajectories using data from KINECT-4, an open-label 52-week trial assessing valbenazine in TD [1] Background: AIMS…Automated VMAT2 [18F]AV-133 PET analysis in Parkinson’s disease
Objective: To evaluate a fully automated image analysis pipeline to process vesicular monoamine transporters type 2 (VMAT2) [18F]AV-133 tracer positron emission tomography (PET) images, by…Real-world effectiveness and safety of deutetrabenazine in patients with chorea associated with Huntington disease
Objective: To assess real-world effectiveness and safety of deutetrabenazine (DTBZ) for chorea associated with Huntington disease (HD). Background: Real-world evidence on the impact of DTBZ…Efficacy and safety of deutetrabenazine in children and adolescents with dyskinesia in cerebral palsy
Objective: To evaluate the efficacy and safety of deutetrabenazine (DTBZ) in children and adolescents with dyskinesia in cerebral palsy (DCP). Background: There are currently no…A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease
Objective: To establish a minimal clinically important difference (MCID) for the Unified Huntington Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score as a measure…Real-World Treatment Patterns and Outcomes in Patients With Chorea Associated With Huntington Disease Using Tetrabenazine or Deutetrabenazine in Combination with Antipsychotic Drugs
Objective: To describe treatment patterns with vesicular monoamine transporter 2 inhibitors (VMAT2i; tetrabenazine [TBZ], or deutetrabenazine [DTBZ]) in combination with antipsychotic agents (APs) in patients…A secretory vesicle failure in Parkinson’s disease occurs in human platelets
Objective: Since platelets use similar, if not the same, mechanisms to accumulate serotonin (5-HT) as dopaminergic neurons to store DA in their VS; we wonder…The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit
Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…Diagnostic value of striatal [18F]-FP-DTBZ PET in Parkinson’s disease
Objective: To detect the difference of dopaminergic integrity between PDs and healthy controls (HC) using [18F]-FP-DTBZ PET in vivo and to obtain the diagnostic value…Long-term Deutetrabenazine Safety on Motor, Psychiatric, and Cognitive Measures in Individuals With Chorea Associated With Huntington Disease
Objective: To evaluate long-term deutetrabenazine safety on motor, psychiatric, and cognitive measures in participants with chorea associated with Huntington disease (HD). Background: Deutetrabenazine, a vesicular…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »